Analysts at Needham & Company LLC began coverage on shares of Iterum Therapeutics (NASDAQ:ITRM) in a report issued on Tuesday. The firm set a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 62.60% from the stock’s current price.
Several other analysts have also commented on the stock. Leerink Swann began coverage on shares of Iterum Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $18.00 price objective on the stock. Guggenheim began coverage on shares of Iterum Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $21.00 price objective on the stock.
Shares of ITRM stock opened at $12.30 on Tuesday. Iterum Therapeutics has a 52 week low of $11.23 and a 52 week high of $13.00.
Iterum Therapeutics Company Profile
There is no company description available for Iterum Therapeutics PLC.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.